101108-a - IMEA
101108-a - IMEA
101108-a - IMEA
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
BENCHMRK: % Patients with RNA < 400 c/mL at Wk 16<br />
●<br />
●<br />
Raltegravir 400 mg b.i.d. vs placebo (randomized 2:1) in combination with OBT<br />
HIV RNA > 1000 c/mL, geno/phenotypic resistance to > 1 drug in each of 3 classes<br />
Median (range)<br />
Mean CD4 count (cells/mm 3 ) 156<br />
% AIDS 94<br />
% GSS < 2 63<br />
Overall Efficacy Data<br />
Efficacy by ARTs in OBT<br />
ENF DRV<br />
80<br />
+ +<br />
+ -<br />
- +<br />
- -<br />
447<br />
230<br />
44<br />
23<br />
42<br />
24<br />
80<br />
47<br />
191<br />
90<br />
79<br />
43<br />
98<br />
87<br />
90<br />
63<br />
90<br />
55<br />
74<br />
29<br />
0 20 40 60 80 100<br />
Raltegravir + OBT<br />
Placebo + OBT<br />
Cooper D, CROI 2007<br />
Steigbigel R, CROI 2007
Change language